Population deworming every 6 months with albendazole in 1 million pre-school children in North India: DEVTA, a cluster-randomised trial
Shally Awasthi,Richard Peto,Simon Read,Susan M Richards,Vinod Pande,Donald Bundy,DEVTA (Deworming and Enhanced Vitamin A) team,Lakshmi Ayyar,Atul Chandra,Vipin Chandra Joshi,Nisha Narang,Hasibur Rehman,Nikhil Saxena,Naveen Prakash,Anuradha Sharma,Monika Sharma,Manish Tripathi,Deepak Kumar Upreti,Rohini Das,Anupama Lal,Tuhina Rastogi,S S Mani,Dheeraj Chitransh,Lalit Pandey,Amit Tandon,Durgesh Bajpai,Umesh Chandra,Arunesh Dwivedi,P K Pant,Vivekanand Shukla,Amir Ahmad,Hafeez Ahmad,Jitendra Bahadur,Harish Chandra,Ramesh Chandra,Anil Chaturvedi,Shailesh Dwivedi,Amar Kumar,Digant Kumar,Mahesh Kumar,Neelu Kumar,Rajesh Kumar,Sudheer Kumar,Sunil Kumar 1st,Sunil Kumar 2nd,Chandra Pal,Mahesh Prasad,Rakesh Kumar 1st,Rakesh Kumar 2nd,Zafar Rashid,Hitler Singh,Hanslal Shukla,Kunj Bihari Shukla,Shiv Shanker Shukla,Vipin Bihari Shukla,Sangram Singh,Satyawan Singh,Shiv Shankar Verma,Shiv Singh Verma,Inamul Haq,Mohammed Kazi,Ajay Kumar,Keshav Kumar,Manoj Kumar,Sharawan Kumar,Bansi Lal,Ashok Kumar Tiwari,Shrawan Awasthi,Alpana Maseeh,Safia Najeeb,Lalji Neetu,Shahnaaz Parween,B Rai,Ajay Sharma,Reetu Shukla,Sudha Shukla,Lalji Shukla,Anuj Srivastava,Vinay Kumar Srivastava
DOI: https://doi.org/10.1016/S0140-6736(12)62126-6
2013-04-27
Abstract:Background: In north India many pre-school children are underweight, many have intestinal worms, and 2-3% die at ages 1·0-6·0 years. We used the state-wide Integrated Child Development Service (ICDS) infrastructure to help to assess any effects of regular deworming on mortality. Methods: Participants in this cluster-randomised study were children in catchment areas of 8338 ICDS-staffed village child-care centres (under-5 population 1 million) in 72 administrative blocks. Groups of four neighbouring blocks were cluster-randomly allocated in Oxford between 6-monthly vitamin A (retinol capsule of 200,000 IU retinyl acetate in oil, to be cut and dripped into the child's mouth every 6 months), albendazole (400 mg tablet every 6 months), both, or neither (open control). Analyses of albendazole effects are by block (36 vs 36 clusters). The study spanned 5 calendar years, with 11 6-monthly mass-treatment days for all children then aged 6-72 months. Annually, one centre per block was randomly selected and visited by a study team 1-5 months after any trial deworming to sample faeces (for presence of worm eggs, reliably assessed only after mid-study), weigh children, and interview caregivers. Separately, all 8338 centres were visited every 6 months to monitor pre-school deaths (100,000 visits, 25,000 deaths at age 1·0-6·0 years [the primary outcome]). This trial is registered at ClinicalTrials.gov, NCT00222547. Findings: Estimated compliance with 6-monthly albendazole was 86%. Among 2589 versus 2576 children surveyed during the second half of the study, nematode egg prevalence was 16% versus 36%, and most infection was light. After at least 2 years of treatment, weight at ages 3·0-6·0 years (standardised to age 4·0 years, 50% male) was 12·72 kg albendazole versus 12·68 kg control (difference 0·04 kg, 95% CI -0·14 to 0·21, p=0·66). Comparing the 36 albendazole-allocated versus 36 control blocks in analyses of the primary outcome, deaths per child-care centre at ages 1·0-6·0 years during the 5-year study were 3·00 (SE 0·07) albendazole versus 3·16 (SE 0·09) control, difference 0·16 (SE 0·11, mortality ratio 0·95, 95% CI 0·89 to 1·02, p=0·16), suggesting absolute risks of dying between ages 1·0 and 6·0 years of roughly 2·5% albendazole versus 2·6% control. No specific cause of death was significantly affected. Interpretation: Existing ICDS village staff can be organised to deliver simple pre-school interventions sustainably for many years at low cost, but regular deworming had little effect on mortality in this lightly infected pre-school population. Funding: UK Medical Research Council, USAID, World Bank (albendazole donated by GlaxoSmithKline).